CA SB1094

Expands pharmacist authority to substitute biosimilar biological products (not just interchangeable biologics) when filling prescriptions, unless the prescriber explicitly indicates "Do not substitute"

Prohibits health insurers from dropping coverage for a previously approved prescription drug if the patient continues to need it and it remains safe, effective, and medically necessary

Allows health plans and insurers to require patients to try lower-cost AB-rated generic equivalents, biosimilars, or interchangeable biological products if the substitute costs the plan less and patient cost-sharing is equal or lower

Requires health plans and insurers to report data on prescription substitutions, including how often substitutions reduce patient cost-sharing and the impact on premiums

Applies to health insurance policies issued, amended, or renewed on or after January 1, 2027